A PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-BLIND, RANDOMISED TRIAL OF EMRICASAN IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND RAISED TRANSAMINASES

被引：19
|
作者：
Shiffman, M. [1 ]
Freilich, B. [2 ]
Vuppalanchi, R. [3 ]
Watt, K. [4 ]
Burgess, G. [5 ]
Morris, M. [5 ]
Sheedy, B. [5 ]
Schiff, E. [6 ]
机构：
[1] Bon Secours Hlth Syst Richmond & Newport News, Liver Inst Virginia, Richmond Newport News, VA USA
[2] Kansas City Res Inst, Kansas City, KS USA
[3] Indiana Univ Sch Med, Div Gastroenterol & Hepatol 3, Indianapolis, IN 46202 USA
[4] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[5] Conatus Pharmaceut Inc, San Diego, CA USA
[6] Univ Miami, Div Hepatol, Miami, FL USA
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)30191-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LP37
引用
收藏
页码：S282 / S282
页数：1
相关论文
共 50 条
  • [21] Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Taheri, Hoda
    Malek, Mojtaba
    Ismail-Beigi, Faramarz
    Zamani, Farhad
    Sohrabi, Masoudreza
    Reza Babaei, Mohammad
    Khamseh, Mohammad E.
    ADVANCES IN THERAPY, 2020, 37 (11) : 4697 - 4708
  • [22] Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
    Stanley, Takara L.
    Fourman, Lindsay T.
    Feldpausch, Meghan N.
    Purdy, Julia
    Zheng, Isabel
    Pan, Chelsea S.
    Aepfelbacher, Julia
    Buckless, Colleen
    Tsao, Andrew
    Kellogg, Anela
    Branch, Karen
    Lee, Hang
    Liu, Chia-Ying
    Corey, Kathleen
    Chung, Raymond T.
    Torriani, Martin
    Kleiner, David E.
    Hadigan, Colleen M.
    Grinspoon, Steven K.
    LANCET HIV, 2019, 6 (12): : E821 - E830
  • [23] A PHASE-2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF ARAMCHOL FOR THE TREATMENT OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Safadi, R.
    Konikoff, F. M.
    Oren, R.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S558 - S558
  • [24] Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial
    Hormoznejad, Razie
    Shahi, Majid Mohammad
    Rahim, Fakher
    Helli, Bijan
    Alavinejad, Pezhman
    Sharhani, Asaad
    INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 2020, 71 (08) : 991 - 1000
  • [25] Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
    Lee, Eunok
    Lim, Yeni
    Kwon, Sung Won
    Kwon, Oran
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2019, 68 : 33 - 41
  • [26] A double-blind, placebo-controlled trial of pioglitazone in the treatment of non-alcoholic steatohepatitis (NASH)
    Harrison, S
    Belfort, R
    Brown, K
    Darland, C
    Finch, J
    Fincke, C
    Havranek, R
    Hardies, J
    Dwivedi, S
    Berria, R
    Tio, FM
    Schenker, S
    Cusi, K
    GASTROENTEROLOGY, 2005, 128 (04) : A681 - A681
  • [27] norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study
    Traussnigg, Stefan
    Schattenberg, Jorn M.
    Demir, Muenevver
    Wiegand, Johannes
    Geier, Andreas
    Teuber, Gerlinde
    Hofmann, Wolf Peter
    Kremer, Andreas E.
    Spreda, Frank
    Kluwe, Johannes
    Petersen, Joerg
    Boettler, Tobias
    Halilbasic, Emina
    Greinwald, Roland
    Proels, Markus
    Manns, Michael P.
    Fickert, Peter
    Trauner, Michael H.
    HEPATOLOGY, 2017, 66 : 106A - 107A
  • [28] Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial
    Darand, Mina
    Darabi, Zahra
    Yari, Zahra
    Saadati, Saeedeh
    Hedayati, Mehdi
    Khoncheh, Ahmad
    Hosseini-Ahangar, Behnam
    Alavian, Seyed Moayyed
    Hekmatdoost, Azita
    COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 44 : 204 - 209
  • [29] The effect of nigella sativa supplementation on cardiometabolic outcomes in patients with non-alcoholic fatty liver: A randomized double-blind, placebo-controlled trial
    Rashidmayvan, Mohammad
    Vandyousefi, Sarvenaz
    Barati, Meisam
    Salamat, Shekoufeh
    Ghodrat, Sara
    Khorasanchi, Maryam
    Jahan-Mihan, Alireza
    Nattagh-Eshtivani, Elyas
    Mohammadshahi, Majid
    COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE, 2022, 48
  • [30] Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial
    Rahmani, Sepideh
    Asgary, Sedigheh
    Askari, Gholamreza
    Keshvari, Mahtab
    Hatamipour, Mahdi
    Feizi, Awat
    Sahebkar, Amirhossein
    PHYTOTHERAPY RESEARCH, 2016, 30 (09) : 1540 - 1548
12345